JP2007277240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007277240A5 JP2007277240A5 JP2007097995A JP2007097995A JP2007277240A5 JP 2007277240 A5 JP2007277240 A5 JP 2007277240A5 JP 2007097995 A JP2007097995 A JP 2007097995A JP 2007097995 A JP2007097995 A JP 2007097995A JP 2007277240 A5 JP2007277240 A5 JP 2007277240A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- anticancer
- composition
- cancer
- anticancer agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78927606P | 2006-04-04 | 2006-04-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007277240A JP2007277240A (ja) | 2007-10-25 |
| JP2007277240A5 true JP2007277240A5 (enExample) | 2010-05-20 |
Family
ID=38421777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007097995A Withdrawn JP2007277240A (ja) | 2006-04-04 | 2007-04-04 | （２Ｒ，Ｚ）−２−アミノ−２−シクロヘキシル−Ｎ−（５−（１−メチル−１Ｈ−ピラゾール−４−イル）−１−オキソ−２，６−ジヒドロ−１Ｈ−［１，２］ジアゼピノ［４，５，６−ｃｄ］インドール−８−イル）アセトアミドの併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090312280A1 (enExample) |
| EP (1) | EP2007375A1 (enExample) |
| JP (1) | JP2007277240A (enExample) |
| KR (1) | KR20080100838A (enExample) |
| CN (1) | CN101415417A (enExample) |
| AR (1) | AR060284A1 (enExample) |
| AU (1) | AU2007232279B2 (enExample) |
| BR (1) | BRPI0709731A2 (enExample) |
| CA (1) | CA2648371A1 (enExample) |
| IL (1) | IL194340A0 (enExample) |
| MX (1) | MX2008012791A (enExample) |
| RU (1) | RU2409361C2 (enExample) |
| TW (1) | TW200806301A (enExample) |
| WO (1) | WO2007113671A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113436A1 (ja) * | 2008-03-14 | 2009-09-17 | 国立大学法人千葉大学 | Ｆｇｆｒ３遺伝子阻害剤の放射線照射併用による放射線の抗癌作用増強法および副作用軽減法 |
| KR20100131457A (ko) * | 2008-03-27 | 2010-12-15 | 다이호야쿠힌고교 가부시키가이샤 | 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제 |
| CN102612365B (zh) * | 2009-04-11 | 2017-04-12 | 阵列生物制药公司 | 用于强化dna损伤剂的检查点激酶1抑制剂 |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| TW201304778A (zh) | 2010-11-16 | 2013-02-01 | Array Biopharma Inc | 檢查點激酶１抑制劑及ｗｅｅ１激酶抑制劑之組合 |
| NO2797921T3 (enExample) | 2011-12-31 | 2018-02-03 | ||
| SG11201403538TA (en) | 2011-12-31 | 2014-09-26 | Beigene Ltd | Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors |
| CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| PL378372A1 (pl) * | 2003-01-09 | 2006-04-03 | Pfizer Inc. | Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii |
-
2007
- 2007-03-26 AU AU2007232279A patent/AU2007232279B2/en not_active Ceased
- 2007-03-26 BR BRPI0709731-0A patent/BRPI0709731A2/pt not_active IP Right Cessation
- 2007-03-26 CN CNA2007800121818A patent/CN101415417A/zh active Pending
- 2007-03-26 US US12/295,986 patent/US20090312280A1/en not_active Abandoned
- 2007-03-26 WO PCT/IB2007/000928 patent/WO2007113671A1/en not_active Ceased
- 2007-03-26 MX MX2008012791A patent/MX2008012791A/es unknown
- 2007-03-26 CA CA002648371A patent/CA2648371A1/en not_active Abandoned
- 2007-03-26 EP EP07734247A patent/EP2007375A1/en not_active Withdrawn
- 2007-03-26 KR KR1020087024155A patent/KR20080100838A/ko not_active Ceased
- 2007-03-26 RU RU2008139406/15A patent/RU2409361C2/ru not_active IP Right Cessation
- 2007-04-03 TW TW096111825A patent/TW200806301A/zh unknown
- 2007-04-03 AR ARP070101414A patent/AR060284A1/es not_active Application Discontinuation
- 2007-04-04 JP JP2007097995A patent/JP2007277240A/ja not_active Withdrawn
-
2008
- 2008-09-25 IL IL194340A patent/IL194340A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023165603A1 (en) | Dna-pk inhibitor and combination use thereof | |
| US11648211B2 (en) | Nanoencapsulated combination drug formulations | |
| ES2964764T3 (es) | Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino | |
| CN103282037B (zh) | 抗肿瘤生物碱的联合治疗 | |
| JP5551589B2 (ja) | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 | |
| JP2010520289A5 (enExample) | ||
| RU2008139406A (ru) | Комдинированная терапия (2r, z)-2-амино-2-циклогексил-n-(1-метил-1н-пиразол-4-ил)-1-оксо-2, 6-дигидо-1н-(1, 2)диазепино(4, 5, 6-d(ндол-8-ил)ацетамидом | |
| KR20120004523A (ko) | Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제 | |
| JP2010180210A5 (enExample) | ||
| JP2013542241A5 (enExample) | ||
| JP2008530248A5 (enExample) | ||
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| JP2011520921A5 (enExample) | ||
| ATE523200T1 (de) | Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel | |
| ES2389809T3 (es) | Terapias anticancerosas | |
| JP2024527974A5 (enExample) | ||
| Hu et al. | Current status of CPT and its analogues in the treatment of malignancies | |
| CN116672345A (zh) | Parp抑制剂和细胞毒性剂的联合产品及其用途 | |
| ES2703739T3 (es) | Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico | |
| Raghavendra | Camptothecin and analogs: role in anticancer activities | |
| Choy et al. | Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer | |
| WO2010081825A2 (en) | Pirenzepine as an agent in cancer treatment | |
| HK1154344B (en) | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent |